首页> 外文期刊>Biochimie >Anticarcinogenesis Pathways Activated By Bovine Lactoferrin In The Murine Small Intestine
【24h】

Anticarcinogenesis Pathways Activated By Bovine Lactoferrin In The Murine Small Intestine

机译:牛乳铁蛋白在小鼠小肠中激活的抗癌途径

获取原文
获取原文并翻译 | 示例
       

摘要

Oral administration of bovine lactoferrin (bLF) inhibits carcinogenesis in the colon and other organs in rats, and lung metastasis in mice. A likely mechanism by which bLF mediates its anticarcinogenesis effects is by enhanced expression of cytokines and subsequent activation of immune cells. Oral administration of bLF enhances expression of interleukin-18 (IL-18) mRNA in the mucosa of the small intestine of mice. Importantly, the pepsin hydrolysate of bLF (bLFH) also induced expression of IL-18 mRNA in the mouse small intestine and a peptide produced by pepsin digestion of bLF, bovine lactoferricin (bLFcin), induced expression of mature IL-18 in organ culture. In addition to IL-18, bLF and bLFcin both induced significant increases in caspase-1 activity in peritoneal macrophages and in organ cultures. The increase of mature IL-18 by macrophages was inhibited by caspase-1 inhibitor: caspase-1 is known to cleave the preform of IL-18 to produce active mature IL-18. Finally, bLF also induced expression of IFN_γ by peritoneal macrophages. Importantly, in IFN_γ knockout (GKO) mice, bLF administration resulted in increased expression of caspase-1 protein, but induction of IL-18 mRNA, caspase-l activity, and mature IL-18 was not observed. These results indicate that orally administered bLF can induce expression of IFN_γ and caspase-1 in the small intestine. IFN_γ in turn increases expression of target genes, including IL-18. Active caspase-1 then cleaves pro-IL-18 to generate mature IL-18. Thus, bLF activates an effector pathway mediated by IFN_γ, caspase-1, and IL-18. We also show that ingested bLF is able to activate more than a single effector pathway. For example, in GKO mice while bLF administration could not activate the IFN_γ/caspase-l/IL-18 effector pathway, it was able to inhibit tumor growth and metastasis by activation of an IFNα/IL-7 effector pathway.
机译:口服牛乳铁蛋白(bLF)抑制大鼠结肠和其他器官的癌变,以及小鼠肺转移。 bLF介导其抗癌作用的可能机制是通过增强细胞因子的表达和随后激活免疫细胞。口服bLF可增强小鼠小肠黏膜中白介素18(IL-18)mRNA的表达。重要的是,bLF的胃蛋白酶水解产物(bLFH)还可诱导小鼠小肠中IL-18 mRNA的表达,而bLF的胃蛋白酶消化产生的肽,牛乳铁蛋白(bLFcin)可诱导器官培养物中成熟IL-18的表达。除IL-18外,bLF和bLFcin均诱导腹膜巨噬细胞和器官培养物中caspase-1活性显着增加。 caspase-1抑制剂抑制了巨噬细胞对成熟IL-18的增加:已知caspase-1可以裂解IL-18的预型体,从而产生活性的成熟IL-18。最后,bLF还诱导腹膜巨噬细胞表达IFN_γ。重要的是,在IFN_γ基因敲除(GKO)小鼠中,bLF给药导致caspase-1蛋白表达增加,但未观察到IL-18 mRNA,caspase-1活性和成熟IL-18的诱导。这些结果表明口服bLF可以诱导小肠中IFN_γ和caspase-1的表达。 IFN_γ继而增加了包括IL-18在内的靶基因的表达。然后,有活性的胱天蛋白酶-1裂解IL-18原以生成成熟的IL-18。因此,bLF激活由IFN_γ,caspase-1和IL-18介导的效应子途径。我们还表明,摄入的bLF不仅可以激活单个效应子途径,还可以激活更多的激活因子。例如,在GKO小鼠中,虽然bLF施用不能激活IFN_γ/ caspase-1 / IL-18效应子途径,但是它能够通过激活IFNα/ IL-7效应子途径抑制肿瘤生长和转移。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号